105 related articles for article (PubMed ID: 28122374)
21. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
22. Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms.
Imaoka H; Sasaki M; Takahashi H; Hashimoto Y; Ohno I; Mitsunaga S; Watanabe K; Umemoto K; Kimura G; Suzuki Y; Ikeda M
Endocr Relat Cancer; 2017 Sep; 24(9):475-483. PubMed ID: 28684542
[TBL] [Abstract][Full Text] [Related]
23. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients.
Shiba S; Morizane C; Hiraoka N; Sasaki M; Koga F; Sakamoto Y; Kondo S; Ueno H; Ikeda M; Yamada T; Shimada K; Kosuge T; Okusaka T
Pancreatology; 2016; 16(1):99-105. PubMed ID: 26718527
[TBL] [Abstract][Full Text] [Related]
25. Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms.
Daskalakis K; Chatzelis E; Tsoli M; Papadopoulou-Marketou N; Dimitriadis GK; Tsolakis AV; Kaltsas G
Endocrine; 2019 May; 64(2):384-392. PubMed ID: 30280284
[TBL] [Abstract][Full Text] [Related]
26. Vitamin D deficiency is widespread in cancer patients and correlates with advanced stage disease: a community oncology experience.
Churilla TM; Brereton HD; Klem M; Peters CA
Nutr Cancer; 2012; 64(4):521-5. PubMed ID: 22452722
[TBL] [Abstract][Full Text] [Related]
27. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
[TBL] [Abstract][Full Text] [Related]
28. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
Yao W; Wang W; Li G
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria.
Sandvik OM; Søreide K; Gudlaugsson E; Kvaløy JT; Søreide JA
Br J Surg; 2016 Feb; 103(3):226-32. PubMed ID: 26511392
[TBL] [Abstract][Full Text] [Related]
30. Vitamin D deficiency among smear positive pulmonary tuberculosis patients and their tuberculosis negative household contacts in Northwest Ethiopia: a case-control study.
Tessema B; Moges F; Habte D; Hiruy N; Yismaw S; Melkieneh K; Kassie Y; Girma B; Melese M; Suarez PG
Ann Clin Microbiol Antimicrob; 2017 May; 16(1):36. PubMed ID: 28490367
[TBL] [Abstract][Full Text] [Related]
31. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
32. Is determination of matrix metalloproteinases and their tissue inhibitors serum concentrations useful in patients with gastroenteropancreatic and bronchopulmonary neuroendocrine neoplasms?
Blicharz-Dorniak J; Kos-Kudła B; Foltyn W; Kajdaniuk D; Marek B; Zemczak A; Strzelczyk J
Endokrynol Pol; 2012; 63(6):470-6. PubMed ID: 23339005
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of Vitamin D Deficiency in Patients Undergoing Elective Spine Surgery: A Cross-Sectional Analysis.
Ravindra VM; Godzik J; Guan J; Dailey AT; Schmidt MH; Bisson EF; Hood RS; Ray WZ
World Neurosurg; 2015 Jun; 83(6):1114-9. PubMed ID: 25535064
[TBL] [Abstract][Full Text] [Related]
34. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
35. Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy.
Krug S; Boch M; Nimphius W; Gress TM; Michl P; Rinke A
Pancreatology; 2017; 17(1):139-145. PubMed ID: 28027897
[TBL] [Abstract][Full Text] [Related]
36. Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy.
Chougnet CN; Leboulleux S; Caramella C; Lumbroso J; Borget I; Déandreis D; Duvillard P; Elias D; de Baere T; Vélayoudom-Céphise FL; Guigay J; Ducreux M; Schlumberger M; Baudin E
Endocr Relat Cancer; 2013 Apr; 20(2):229-39. PubMed ID: 23404855
[TBL] [Abstract][Full Text] [Related]
37. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
Chiti A; van Graafeiland BJ; Savelli G; Ferrari L; Seregni E; Castellani MR; Bombardieri E
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S190-4. PubMed ID: 10604128
[TBL] [Abstract][Full Text] [Related]
38. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study.
Massironi S; Campana D; Pusceddu S; Albertelli M; Faggiano A; Panzuto F; Smiroldo V; Andreasi V; Rossi RE; Maggio I; Torchio M; Dotto A; Modica R; Rinzivillo M; Carnaghi C; Partelli S; Fanetti I; Lamberti G; Corti F; Ferone D; Colao A; Annibale B; Invernizzi P; Falconi M;
Dig Liver Dis; 2021 Mar; 53(3):367-374. PubMed ID: 33645508
[TBL] [Abstract][Full Text] [Related]
39. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms.
Panzuto F; Cicchese N; Partelli S; Rinzivillo M; Capurso G; Merola E; Manzoni M; Pucci E; Iannicelli E; Pilozzi E; Rossi M; Doglioni C; Falconi M; Delle Fave G
PLoS One; 2017; 12(6):e0179445. PubMed ID: 28644861
[TBL] [Abstract][Full Text] [Related]
40. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors.
Gabriel M; Muehllechner P; Decristoforo C; von Guggenberg E; Kendler D; Prommegger R; Profanter C; Moncayo R; Virgolini I
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):237-44. PubMed ID: 16172569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
